Clinical and epidemiological characteristics of patients with COVID-19 at a high-altitude hospital
DOI:
https://doi.org/10.24265/horizmed.2021.v21n2.09Keywords:
Coronavirus infections, Epidemiology, Mortality, HypertensionAbstract
Objective: To determine the clinical and epidemiological characteristics of patients with COVID-19 at a high-altitude hospital. Materials and methods: An observational, cross-sectional and analytical study carried out at the Hospital Daniel Alcides Carrión in Huancayo, Peru, located at 3,250 m a.s.l. The population consisted of 2,248 people. COVID-19 was diagnosed through serology testing and/or reverse transcription polymerase chain reaction (RT-PCR) testing. Data were recorded in a questionnaire. For the statistical analysis, the X2 test, Student’s t-test, and bivariate and multivariate logistic regression analyses were used. A p value < 0.05 was considered statistically significant. Results: The study population with a diagnosis of COVID-19 accounted for 760 patients (100 %), most of whom were males (474 individuals; 62.36 %). The average age was 49 years (range: 15 to 95). Most cases were found in the age group of 40 to 59 years (38.82 %), particularly among housewives (21.44 %) and traders (19.21 %). The most common COVID-19 symptoms were cough (70.26 %), malaise (57.63 %), respiratory distress (48.81 %), fever (48.15 %) and sore throat (44.21 %). The most frequent comorbidities were obesity (4.47 %), diabetes mellitus (2.76 %) and arterial hypertension (1.31 %). Fifty-one point seven one percent (51.71 %) of the patients required hospitalization and the mortality rate was 14.21 %. The risk factors for mortality were age 60 years or older (OR = 4.74; 95 % CI: 2.94 - 7.65; p = 0.000), respiratory distress (OR = 2.38; 95 % CI: 1.42 - 3.99; p = 0.001) and use of mechanical ventilation (OR = 8.75; 95 % CI: 4.45 - 17.22; p = 0.000). Conclusions: COVID-19 most frequently affects the adult population. Cough and malaise were the most common symptoms, while older age, dyspnea and use of mechanical ventilation were associated with a higher risk of mortality.
Downloads
References
Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020; 35(5): 1545-9.
Yan-Rong G, Qing-Dong C, Zhong-Si H, Yuan-Yang T, Shou-Deng C, Hong-Jun J, et al. The origin, transmission, and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1): 11.
Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020; 11: 29.
Pascarella G, Strumia A, Piliego C, Bruno F, Buono RD, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020; 288(2): 192-206.
Shi Y, Wang G, Cai X-P, Deng J-W, Zheng L, Zhu H-H, et al. An overview of COVID-19. J Zhenjiang Univ Sci B. 2020; 21(5): 343-60.
Li H, Liu S-M, Yu X-H, Tang S-L, Tang C-K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020; 55(5): 105951.
Ge H, Wang X, Yuan X, Xiao G, Wang Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020; 39(6): 1011-9.
Tadic M, Cuspidi C, Mancia G, Dell’Oro R, Grassi G. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?. Pharmacol Res. 2020; 158: 104906.
Ministerio de Salud. Alerta epidemiológica ante riesgo de intensificación de la transmisión comunitaria de COVID-19 en el periodo post cuarentena, en el Perú [Internet]. Lima; 2020. Disponible en: https://www.dge.gob.pe/portal/docs/alertas/2020/AE019.pdf
Hoffman T, Nissen K, Krambich J, Rönnberg B, Akaberi D, Esmaeilzadeh M, et al. Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2. Infect Ecol Epidemiol. 2020; 10(1): 1754538.
Instituto Nacional de Estadística e Informática. Perú: factores de riesgo asociados a complicaciones por COVID-19. ENDES 2018-2019 [Internet]. Lima: 2020. Disponible en: https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/ Est/Lib1738/libro.pdf
Organización Panamericana de la Salud. Definiciones de casos para la vigilancia COVID-19 – 16 de diciembre del 2020 [Internet]. OPS; 2020. Disponible en: https://www.paho.org/es/temas/coronavirus/brote-enfermedad-por-coronavirus-covid-19/definiciones-casos-para-vigilancia
Escobar G, Matta J, Ayala R, Amado J. Características epidemiológicas de pacientes fallecidos por COVID-19 en un Hospital Nacional de Lima, Peru. Rev Fac Med Hum. 2020; 20(2): 180-5.
Tenda ED, Yulianti M, Asaf MM, Yunus RE, Septiyanti W, Wulani V, et al. The importance of chest CT Scan in COVID-19. Acta Med Indones. 2020: 52(1): 68-73.
Moran KR, Del Valle SY. A meta-analysis of the association betwween gender and protective behaviors in response to respiratory epidemics and pandemics. PLoS One. 2016; 11(10): e0164541.
Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020; 55(5): 2000547.
Yusuf MMF, Garad MY, Mohamed AA, Adam AB. Loss of taste and smell are common clinical characteristics of patients with COVID-19 in Somalia: A retrospective double centre study. Infec Drug Resist. 2020; 13: 2631-5.
Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020; 26(6): 767-72.
Guzman-Del Giudice OE, Lucchesi-Vásquez EO, Trelles-De Belaúnde M, Pinedo-Gonzales RH, Daly A, et al. Características clínicas y epidemiológicas de 25 casos de COVID-19 atendidos en la Clínica Delgado de Lima. Rev Soc Per Med Interna. 2020; 33(1): 15-24.
Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and short-term outcoms of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020; 127: 104364.
Cantero MTR. Las estadísticas sanitarias y la invisibilidad por sexo y de género durante la epidemia de COVID-19. Gac Sanit. 2021; 35(1): 95-8.
Mukherjee S, Pahan K. Is COVID-19 Gender-sensitive?. J Neuroimmune Pharmacol. 2021; 1-10.
Gadi N, Wu SC, Spihlman AP, Moulton VR. What’s sex got to do with COVID-19? Gender-based differences in the host immune response to coronaviruses. Front Immunol. 2020; 11: 2147.
Mangia C, Russo A, Civitelli S, Gianicolo EAL. Sex/gender differences in COVID-19 lethality: what the data say, and do not say. Epidemiol Prev. 2020; 44 (5-6 Suppl. 2): 400-6.
Pradhan A, Olsson P-E. Sex differences in severity and mortality from COVID-19: are males more vulnerable?. Biol Sex Differ. 2020; 11(1): 53.
Hall KS, Samari G, Garbers S, Casey SE, Diallo DD, Orcutt M, et al. Centring sexual and reproductive health and justice in the global COVID-19 response. Lancet. 2020; 395(10231): 1175-7.
Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics if COVID-19 infection in Beijing. J Infect. 2020; 80(4): 401-6.
Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020; 215: 108427.
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2029 (COVID-19) from publicly reported confirmed cases: Estimation and Application. Ann Intern Med. 2020: M20-0504.
Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID-19 and clinical hematology laboratory. Int J Lab Hematol. 2020; 42(Suppl. 1): 11-8.
Du R-H, Liang L-R, Yang C-Q, Wang W, Cao T-Z, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020; 55(5): 2000524.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708-20.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507-13.
Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID‐19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20(4): 425-34.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506.
Lai CL, Shih TP, Ko WC, Tang HJ, Hsuch PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020; 55(3): 105924.
Kabir T, Uddin S, Hossain F, Abdulhakim J, Alam A, Asrhaf G., et al. nCOVID-19 pandemic: from molecular pathogenesis to potential investigational therapeutics. Front Cell Dev Biol. 2020; 8: 616.
Yang C-L, Qiu X, Zeng Y-K, Jiang M, Fan H-R, Zhang Z-M. Coronavirus disease 2019: a clinical review. Eur Rev Med Pharmacol Sci. 2020; 24 (8): 4585-96.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506.
Mejía F, Medina C, Cornejo E, Morello E, Vásquez S, Alave J, et al. Características clínicas y factores asociados a mortalidad en pacientes adultos hospitalizados por COVID-19 en un hospital público de Lima, Perú. Preprints Scielo. 2020.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS‐CoV‐2 pneumonia in Wuhan, China: a single‐centered, retrospective, observational study. Lancet Resp Med. 2020; 8(5): 475-81.
Llaro-Sánchez MK, Gamarra-Villegas BE, Campos-Correa KE. Características clínico-epidemiológicas y análisis de sobrevida en fallecidos por COVID-19 atendidos en establecimientos de la Red Sabogal Callao. 2020. Horiz Med. 2020; 20(2): e1229.
Blagosklonny M. From causes of aging to death from COVID-19. Aging (Albany NY). 2020; 12(11): 10004-21.
Uddin M, Mustafa F, Rizvi TA, Loney T, Suwaidi HA, AL-Marzouqi AH, et al. SARS-CoV-2/COVID-19: Viral genomics epidemiology vaccines and therapeutic interventions. Viruses. 2020; 12(5): 526.
Accinelli RA, Leon-Abarca JA. At high altitude COVID-19 is less frequent the experience of Peru. Arch Bronconeumol. 2020; 56(11): 760-1.
Quevedo-Ramirez A, Al-Kassab-Cordova A, Mendez-Guerra C, Cornejo-Venegas G, Alva-Chavez KP. Altitude and excess mortality during COVID-19 pandemic in Peru. Respir Physiol Neurobiol. 2020; 281: 103512.
Segovia-Juarez J, Castagnetto JM, Gonzales GF. High altitude reduces infection rate of COVID-19 but no case fatality rate. Respir Physiol Neurobiol. 2020; 281: 103494.
Cano-Pérez E, Torres-Pacheco J, Fragozo-Ramos MC, García-Díaz G, Montalvo-Varela E, Pozo-Palacios JC. Negative correlation between altitude and the COVID-19 pandemic in Colombia: a preliminary report. Am J Trop Hyg. 2020; 103(6): 2347-9.
Woolcott OO, Bergman RN. Mortality attributed to COVID-19 in high altitude populations. High Alt Med Biol. 2020; 21(4): 409-16.
Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vásquez A, Gonzáles-Díaz A, Márquez-Salinas A, et al. Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. J Clin Endocrinol Metab. 2020; 105(8): dgaa346.
Yu C, Lei Q, Li W, Wang X, Liu W, Fan X, et al. Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: A retrospective study in Wuhan, China. Am J Prev Med. 2020; 59(2): 168-75.
Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020; 81(2): e16-25.
Shi L, Wang Y, Wang Y, Duan G, Yang H. Dyspnea rather than fever is a risk factor for predicting mortality in patients with COVID-19. J Infect. 2020; 81(4): 647-9.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
